



**DIAGNOSTIC REPORT** 

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd M/S S.S. WELLNESS CENTRE,GROUND FLOOR,C-22,SHASTRI NAGAR,NEAR CENTRAL ACADEMY SCHOOL JODHPUR, 342001 RAJASTHAN, INDIA Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

Test Report Status <u>Fin</u>	al Results	Biological Reference Interval Units
REFERRING DOCTOR : DR. B	OB PKG	CLIENT PATIENT ID :
DRAWN :	RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53
ACCESSION NO : 0061WAC	00125 AGE : 29 Years SEX : Male	ABHA NO :
PATIENT NAME : AKASH	GEHLOT 143766	PATIENT ID : AKASM17019461

#### MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

BLOOD COUNTS, EDTA WHOLE BLOOD				
HEMOGLOBIN (HB)	16.5		13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT	5.96	High	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT	6.94		4.0 - 10.0	thou/µL
PLATELET COUNT	322		150 - 410	thou/µL
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	52.8	High	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV)	88.6		83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.7		27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.3	Low	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	13.7		11.6 - 14.0	%
MENTZER INDEX	14.9			
MEAN PLATELET VOLUME (MPV)	10.6		6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	59		40 - 80	%
LYMPHOCYTES	29		20 - 40	%
MONOCYTES	08		2 - 10	%
EOSINOPHILS	04		1 - 6	%
BASOPHILS	00		< 1 - 2	%
MORPHOLOGY				
RBC	RED BLOOD CELLS A	RE NC	ORMOCYTIC NORMOCHROMIC	
WBC	WBCS ARE NORMAL	IN NU	JMBER & MORPHOLOGY	
PLATELETS	PLATELETS ARE ADEC	QUATE	IN NUMBER	
ERYTHROCYTE SEDIMENTATION RATE (ESR),W BLOOD	/HOLE			
E.S.R	05		0 - 14	mm at 1 hr
METHOD : WESTERGREN METHOD				
GLUCOSE FASTING, FLUORIDE PLASMA				
FBS (FASTING BLOOD SUGAR)	90		74 - 99	mg/dL
METHOD : SPECTROPHOTOMETRY				
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA	WHOLE			



BLOOD









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd M/S S.S. WELLNESS CENTRE,GROUND FLOOR,C-22,SHASTRI NAGAR,NEAR CENTRAL ACADEMY SCHOOL JODHPUR, 342001 RAJASTHAN, INDIA Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

CLIENT PATIENT ID:

ABHA NO :

REPORTED :

> 11.0 High Risk

# PATIENT NAME: AKASH GEHLOT 143766

PATIENT ID : AKASM17019461

17/01/2023 19:53

ACCESSION NO :	0061WA00125	AGE :	29 Years	SEX : Male
DRAWN :		RECE	IVED : 17/01	/2023 18:24

# REFERRING DOCTOR : DR. BOB PKG

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
HBA1C	5.2		Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
ESTIMATED AVERAGE GLUCOSE(EAG)	102.5		< 116.0	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA				
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : SPECTROPHOTOMETRY	95		70 - 139	mg/dL
LIPID PROFILE, SERUM CHOLESTEROL, TOTAL METHOD : SPECTROPHOTOMETRY	238	High	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
TRIGLYCERIDES	89		< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : SPECTROPHOTOMETRY HDL CHOLESTEROL	54		< 40 Low >/=60 High	mg/dL
METHOD : SPECTROPHOTOMETRY				
CHOLESTEROL LDL	166	High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
NON HDL CHOLESTEROL	184	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	17.8		= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	4.4		3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk	











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd M/S S.S. WELLNESS CENTRE,GROUND FLOOR,C-22,SHASTRI NAGAR,NEAR CENTRAL ACADEMY SCHOOL JODHPUR, 342001 RAJASTHAN, INDIA Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

PATIENT NAME	: AKASH GEHLO	143766	PATIENT ID : AKASM17019461
ACCESSION NO :	0061WA00125	AGE : 29 Years SEX : Male	ABHA NO :
DRAWN :		RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53
REFERRING DOCT	FOR: DR. BOB PKG		CLIENT PATIENT ID:
Test Report Sta	atus <u>Final</u>	Results	Biological Reference Interval Units

LDL/HDL RATIO

3.1

High 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk









CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd M/S S.S. WELLNESS CENTRE,GROUND FLOOR,C-22,SHASTRI NAGAR,NEAR CENTRAL ACADEMY SCHOOL JODHPUR, 342001 RAJASTHAN, INDIA Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

ACCESSION NO : <b>0061WA00125</b> AGE :       29 Years       SEX :       Male       ABHA NO :         DRAWN :       RECEIVED :       17/01/2023 18:24       REPORTED :       17/01/2023 19:53         REFERRING DOCTOR :       DR. BOB PKG       CLIENT PATIENT ID :	its
^	
PATIENT NAME : AKASH GEHLOT 143766 PATIENT ID : AKASM170	19461

# Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.

2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

<b>Risk Category</b>			
Extreme risk group	A.CAD with $> 1$ feature of high risk group		
	B. CAD with $> 1$ feature of Very high risk g	group or recurrent ACS (within 1 year) despite LDL-C	
	< or $=$ 50 mg/dl or polyvascular disease		
Very High Risk		najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk		betes with 1 major risk factor or no evidence of end	
		DL $>190 \text{ mg/dl} 5$ . Extreme of a single risk factor. 6.	
	Coronary Artery Calcium - CAC >300 AU.	7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid	
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Ath	erosclerotic cardiovascular disease) Risk Fa	ictors	
1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females		3. Current Cigarette smoking or tobacco use	
2. Family history of p	mily history of premature ASCVD 4. High blood pressure		
5. Low HDL			

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy		
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)	









**CLIENT'S NAME AND ADDRESS :** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110000 NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR, NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.iodhpur@gmail.com

CLIENT PATIENT ID:

**Biological Reference Interval** Units

# PATIENT NAME: AKASH GEHLOT 143766

#### PATIENT ID: AKASM17019461

ACCESSION NO : 0061WA00125 AGE : 29 Years SEX : Male ABHA NO : RECEIVED : 17/01/2023 18:24 17/01/2023 19:53 DRAWN : **REPORTED** :

**REFERRING DOCTOR:** DR. BOB PKG

Test Report Status	inal
--------------------	------

Extreme Risk Group Category A	<50 (Optional goal < OR = 30 )	< 80 (Optional goal <or 60<="" =="" math="">)</or>	>OR = 50	>OR = 80
Extreme Risk Group	<or 30<="" =="" td=""><td><math>\langle OR = 60 \rangle</math></td><td>&gt; 30</td><td>&gt;60</td></or>	$\langle OR = 60 \rangle$	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

Results

\*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

Ś

## LIVER FUNCTION PROFILE, SERUM

LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL	1.20	High	0.2 - 1.0	mg/dL
METHOD : SPECTROPHOTOMETRY				
BILIRUBIN, DIRECT	0.10		0.0 - 0.2	mg/dL
METHOD : SPECTROPHOTOMETRY				
BILIRUBIN, INDIRECT	1.10	High	0.1 - 1.0	mg/dL
METHOD : SPECTROPHOTOMETRY				
TOTAL PROTEIN	7.8		6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY				
ALBUMIN	4.2		3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY				
GLOBULIN	3.6		2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER				
ALBUMIN/GLOBULIN RATIO	1.2		1.0 - 2.1	RATIO
METHOD : CALCULATED PARAMETER				
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	25		15 - 37	U/L
METHOD : SPECTROPHOTOMETRY				
ALANINE AMINOTRANSFERASE (ALT/SGPT)	24		< 45.0	U/L
METHOD : SPECTROPHOTOMETRY				
ALKALINE PHOSPHATASE	90		30 - 120	U/L
METHOD : SPECTROPHOTOMETRY				
GAMMA GLUTAMYL TRANSFERASE (GGT)	35		15 - 85	U/L
METHOD : SPECTROPHOTOMETRY				
LACTATE DEHYDROGENASE	149		100 - 190	U/L
METHOD : SPECTROPHOTOMETRY				











ACCESSION NO :

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd M/S S.S. WELLNESS CENTRE,GROUND FLOOR,C-22,SHASTRI NAGAR,NEAR CENTRAL ACADEMY SCHOOL JODHPUR, 342001 RAJASTHAN, INDIA Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

CLIENT PATIENT ID:

REPORTED :

# PATIENT NAME: AKASH GEHLOT 143766

0061WA00125

PATIENT ID : AKASM17019461

17/01/2023 19:53

AGE : 29 Years SEX : Male ABHA NO :	AGE :	29 Years	SEX : Male	ABHA NO :	
-------------------------------------	-------	----------	------------	-----------	--

DRAWN : RECEIVED : 17/01/2023 18:24

REFERRING DOCTOR : DR. BOB PKG

Test Report Status <u>Final</u>	Results	<b>Biological Reference</b>	Interval Units
BLOOD UREA NITROGEN	14	6 - 20	mg/dL
METHOD : SPECTROPHOTOMETRY			
CREATININE, SERUM			
CREATININE	1.21	0.90 - 1.30	mg/dL
METHOD : SPECTROPHOTOMETRY			
BUN/CREAT RATIO			
BUN/CREAT RATIO	11.57	5.00 - 15.00	
METHOD : SPECTROPHOTOMETRY			
URIC ACID, SERUM			
URIC ACID	5.6	3.5 - 7.2	mg/dL
METHOD : SPECTROPHOTOMETRY			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.8	6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY			
ALBUMIN, SERUM			
ALBUMIN	4.2	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY			
GLOBULIN			
GLOBULIN	3.6	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	141	136 - 145	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
POTASSIUM, SERUM	4.3	3.50 - 5.10	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
CHLORIDE, SERUM	106	98 - 107	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			







Patient Ref. No. 775000002160747



# CLIENT CODE : C000138375

CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR, NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com

# PATIENT NAME: AKASH GEHLOT 143766

# PATIENT ID : AKASM17019461

ACCESSION NO :	0061WA00125	AGE: 29 Ye	ars SEX : Male	ABHA NO :	
DRAWN :		RECEIVED :	17/01/2023 18:24	REPORTED :	17/01/2023 19:53

# REFERRING DOCTOR : DR. BOB PKG

Test Report	: Status	<u>Final</u>
-------------	----------	--------------

Results

Biological Reference Interval Units

CLIENT PATIENT ID:

# Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake,prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy,adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia),alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide,carbamazepine,anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative,corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea),diabetes	acidosis, dehydration,renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice, oral contraceptives.	potassium- sparing diuretics,NSAIDs,	alkalosis, hyperadre no corticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, and rogens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

#### PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW	
APPEARANCE	HAZY	
CHEMICAL EXAMINATION, URINE		
PH	7.5	4.7 - 7.5
SPECIFIC GRAVITY	1.020	1.003 - 1.035
PROTEIN	NOT DETECTED	NOT DETECTED
GLUCOSE	NOT DETECTED	NOT DETECTED
KETONES	NOT DETECTED	NOT DETECTED
BLOOD	NOT DETECTED	NOT DETECTED
BILIRUBIN	NOT DETECTED	NOT DETECTED
UROBILINOGEN	NORMAL	NORMAL
NITRITE	NOT DETECTED	NOT DETECTED
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

#### MICROSCOPIC EXAMINATION, URINE











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd M/S S.S. WELLNESS CENTRE,GROUND FLOOR,C-22,SHASTRI NAGAR,NEAR CENTRAL ACADEMY SCHOOL JODHPUR, 342001 RAJASTHAN, INDIA Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com

CLIENT PATIENT ID:

# PATIENT NAME: AKASH GEHLOT 143766

PATIENT ID : AKASM17019461

ACCESSION NO :	0061WA00125	AGE : 29 Years SEX : Male	ABHA NO :
DRAWN :		RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53

REFERRING DOCTOR : DR. BOB PKG

Test Report Status <u>Final</u>	Results	Biological Reference Interva	al Units
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	1-2	0-5	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	Detected (+) Amourphous Phosphate	<u> </u>	
BACTERIA	DETECTED (OCCASIONAL)	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	











CLIENT'S NAME AND ADDRESS : ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR, NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com

Test Report Status	Final	Results	Biological Reference I	nterval Units
REFERRING DOCTOR : D	R. BOB PKG		CLIENT PATIENT ID :	
DRAWN :	RECEIVE	D: 17/01/2023 18:24	REPORTED : 17/01/202	3 19:53
ACCESSION NO : 0061	<b>WA00125</b> AGE : 29	Years SEX : Male	ABHA NO :	
PATIENT NAME: AKASH GEHLOT 143766			PATIENT ID :	AKASM17019461

# Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions		
Proteins	Inflammation or immune illnesses		
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind		
	of kidney impairment		
Glucose	Diabetes or kidney disease		
Ketones	Diabetic ketoacidosis (DKA), starvation o	r thirst	
Urobilinogen	Liver disease such as hepatitis or cirrhosis		
Blood	Renal or genital disorders/trauma		
Bilirubin	Liver disease		
Erythrocytes	Urological diseases (e.g. kidney and bladd	ler cancer, urolithiasis), urinary	
	tract infection and glomerular diseases		
Leukocytes	Urinary tract infection, glomerulonephritis		
	acute or chronic, polycystic kidney disease	e, urolithiasis, contamination by	
	genital secretions		
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or		
	bladder catheters for prolonged periods of time		
Granular Casts	Low intratubular pH, high urine osmolality	y and sodium concentration,	
	interaction with Bence-Jones protein		
Hyaline casts	Physical stress, fever, dehydration, acute c	congestive heart failure, renal	
	diseases		
Calcium oxalate	Metabolic stone disease, primary or second		
	infusion of large doses of vitamin C, the u		
	oxalate or the gastrointestinal lipase inhibi		
	ethylene glycol or of star fruit (Averrhoa c	earambola) or its juice	
Uric acid	arthritis		
Bacteria	Urinary infectionwhen present in significa	nt numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis		
HYROID PANEL, SERUM			
3	107.40 80.00 - 200.00		
7	6.01	E 10 14 10	

ng/dL T4 6.81 5.10 - 14.10 µg/dL TSH (ULTRASENSITIVE) 4.380 High 0.270 - 4.200 µIU/mL









**CLIENT'S NAME AND ADDRESS :** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR, NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com

	TOR : DR. BOB PKG	RECEIVED : 17/01/2023 18:24	CLIENT PATIENT ID :
DRAWN :	A	RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53
ACCESSION NO :	0061WA00125	AGE : 29 Years SEX : Male	ABHA NO :
PATIENT NAME	: AKASH GEHLOT	143766	PATIENT ID : AKASM17019461

5

# Interpretation(s)

Triiodothyronine T3. Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism.Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	<ul> <li>(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre</li> <li>(3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy</li> </ul>
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

## ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	TYPE A
METHOD : FORWARD/REVERSE	
RH TYPE	POSITIVE
METHOD : FORWARD/REVERSE	









**CLIENT'S NAME AND ADDRESS :** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR, NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : DR. BOB PKG		CLIENT PATIENT ID:
DRAWN :	RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53
ACCESSION NO : 0061WA00125	AGE : 29 Years SEX : Male	ABHA NO :
PATIENT NAME : AKASH GEHLOT	PATIENT ID : AKASM17019461	

#### Interpretation(s)

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

# **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

#### ITMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin,

#### ethanol, propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and< 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes. 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for







Patient Ref. No. 775000002160747



# **CLIENT CODE :** C000138375

**CLIENT'S NAME AND ADDRESS :** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR, NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com

Test Report Status Final	Results	Biological Reference Interval Units
REFERRING DOCTOR : DR. BOB PKC	3	CLIENT PATIENT ID :
DRAWN :	RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53
ACCESSION NO : 0061WA00125	AGE : 29 Years SEX : Male	ABHA NO :
PATIENT NAME : AKASH GEHLO	PATIENT ID : AKASM17019461	

well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

#### HbA1c Estimation can get affected due to :

I. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will faisely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

N.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget"""'s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson"""'s disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas.It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, billary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH. CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
  Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers

Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: • Myasthenia Gravis

Muscular dystroph

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis TOTAL PROTEIN, SERUM-Serum total protein,also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic









**CLIENT'S NAME AND ADDRESS :** ACROFEMI HEALTHCARE LTD ( MEDIWHEEL ) F-703, LADO SARAI, MEHRAULI SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd
M/S S.S. WELLNESS CENTRE, GROUND FLOOR, C-22, SHASTRI
NAGAR,NEAR CENTRAL ACADEMY SCHOOL
JODHPUR, 342001
RAJASTHAN, INDIA
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
<b>REFERRING DOCTOR :</b> DR. BOB PKG		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 17/01/2023 18:24	REPORTED : 17/01/2023 19:53
ACCESSION NO : 0061WA00125	AGE : 29 Years SEX : Male	ABHA NO :
PATIENT NAME : AKASH GEHLOT	PATIENT ID : AKASM17019461	

#### syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

\*\*End Of Report\*\* Please visit www.srlworld.com for related Test Information for this accession

Dr. Itisha Dhiman

Pathologist

#### **CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form. 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services. 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

- 4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes. 9. In case of queries please call customer care

(91115 91115) within 48 hours of the report.

#### SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



